INTRODUCTION {#s1}
============

Identification of reliable and specific cancer biomarkers, which would help to diagnose, classify and predict disease outcome is still a challenging task. This is particularly true for malignant melanoma (MM), because only a small quantity of tissue is available at the time of diagnosis. Routinely, melanoma are classified using histological parameters such as tumor thickness and ulceration, serum levels of lactate dehydrogenase (LDH) or staining intensity for S100B protein \[[@R1]\].

During melanoma growth and progression in the adult, developmental genes important for melanocyte differentiation are re-activated. Identification of more of these genes in an adequate *in vivo* experiment might uncover novel melanoma markers. During zebrafish fin regeneration after amputation, melanocyte precursor cells give rise to pigment-producing cells in the new blastema tissue, thereby mimicking the process of melanocyte differentiation in a short time frame \[[@R2]\]. Using microrarrays we compared normal fin tissue to regenerating blastema after amputation and investigated upregulated genes in the Oncomine cancer database \[[@R3]\] to identify those increased in melanoma. Interestingly, we found that 40% of the blastema-upregulated genes are also overexpressed in melanoma. These include known melanoma-promoting proteins such as fibronectin and tenascin C \[[@R4], [@R5]\], but also novel promising candidates such as BAMBI, a negative regulator of TGF-beta signaling \[[@R6]\]. The role of MARCKS in cell motility during melanoma progression is poorly understood \[[@R7]\]. FK506-binding proteins bind to immunosuppressive drugs such as Tacrolimus (FK506), which is used to treat patients after organ transplantation. Members of this family have been shown to be promising new targets in anticancer therapy \[[@R8]\]. FK506 family member FKBP51 promotes melanoma metastasis *in vivo* \[[@R9]\] but nothing is known about the role of FKBP7, 10 and 11 in melanoma growth. Data provided in this paper also show that high expression of FKBP7 is associated with poor survival.

We further studied overexpression at the protein level of these candidates in melanoma lesions. No or very low expression was observed in control skin. Additional co-expression studies with defined gene signatures using Oncomine suggest an association of BAMBI and FKBP10 with the angiogenic process in melanoma and with regeneration after HRAS induced cell transformation, respectively. Taken together, our results suggest that some of the genes induced in physiological regeneration hold the potential to play roles in melanoma malignancy and warrant further functional *in vitro* and *in vivo* studies.

RESULTS {#s2}
=======

Microarray and oncomine expression data {#s2_1}
---------------------------------------

To find genes strongly induced in regenerating blastema we applied a stringent 4-fold-change cut off to significantly regulated genes in our microarray experiments (Figure [1](#F1){ref-type="fig"}). 54 genes detected by 71 probes fulfilled this criterion (Table [1](#T1){ref-type="table"}). Since melanocyte differentiation takes place during blastema development and genes participating in this process are deregulated in MM initiation and progression (reviewed in \[[@R2]\]), we determined expression levels of our regeneration genes in public available datasets of melanoma transcriptome studies using Oncomine. 40 percent of the regeneration genes were overexpressed in melanoma, either compared to normal skin (12/54, Figure [2A](#F2){ref-type="fig"}) or compared to other cancers (10/54; Table [1](#T1){ref-type="table"}).

![(**A**) Regenerating zebrafish tissue used for gene expression analysis. (**B**) Gene selection pipeline leading to the identification of novel melanoma overexpressed genes.](oncotarget-07-71567-g001){#F1}

###### Fifty-four genes (detected by 71 probes) were significantly overexpressed at least 4-fold in regenerating blastema compared to normal fins

  Gene Symbol          Gene Name                                                                        Up in blastema (foldchange)   *P*-value      *q*-value (adj *p*-value)   Melanoma vs normal / other cancers (foldchange)   *P*-value
  -------------------- -------------------------------------------------------------------------------- ----------------------------- -------------- --------------------------- ------------------------------------------------- --------------
  adam8a               a disintegrin and metalloproteinase domain 8a (adam8a)                           35.53                         1.55E-10       2.46E-06                                                                      
  bambi                BMP and activin membrane-bound inhibitor (Xenopus laevis) homolog                4.69                          5.54E-06       4.09E-04                    5.556                                             4.21E-05
  **bambi**            **BMP and activin membrane-bound inhibitor (Xenopus laevis) homolog**            **4.69**                      **5.54E-06**   **4.09E-04**                **10.761**                                        **8.14E-25**
  BC049329             mRNA similar to exportin 1, CRM1 homolog (yeast)                                 8.89                          1.55E-09       4.05E-06                                                                      
  bcan                 brevican (bcan)                                                                  5.36                          5.34E-08       2.13E-05                    22.309                                            7.56E-19
  bcl2l10              BCL2-like 10 (apoptosis facilitator) (bcl2l10)                                   5.87                          1.24E-08       9.48E-06                                                                      
  bcl2l10              BCL2-like 10 (apoptosis facilitator) (bcl2l10)                                   8.52                          3.22E-09       5.62E-06                                                                      
  calua                calumenin a (calua)                                                              10.29                         9.67E-10       3.90E-06                    24.953                                            4.70E-7
  col10a1              collagen, type X, alpha 1 (col10a1)                                              24.23                         1.18E-05       6.39E-04                    5.614                                             4.48E-5
  col10a1              collagen, type X, alpha 1 (col10a1)                                              28.45                         6.77E-06       4.62E-04                    5.614                                             4.48E-5
  col1a1               collagen, type I, alpha 1 (col1a1)                                               9.47                          3.74E-05       1.30E-03                                                                      
  col1a1               collagen, type I, alpha 1 (col1a1)                                               20.28                         1.21E-06       1.63E-04                                                                      
  crip2                cysteine-rich protein 2 (crip2)                                                  11.54                         1.62E-07       4.05E-05                                                                      
  **cygb1**            **cytoglobin 1 (cygb1)**                                                         **27.61**                     **7.15E-09**   **7.26E-06**                **5.76**                                          **2.76E-10**
  **cygb1**            **cytoglobin 1 (cygb1)**                                                         **36.88**                     **2.21E-09**   **4.60E-06**                **5.76**                                          **2.76E-10**
  dachc                dachshund c (dachc)                                                              6.39                          1.11E-08       8.95E-06                                                                      
  dkk1                 dickkopf 1 (dkk1)                                                                4.08                          3.03E-06       2.86E-04                                                                      
  dlx4a                distal-less homeobox gene 4a (dlx4a)                                             4.56                          1.10E-07       3.23E-05                                                                      
  dlx4a                distal-less homeobox gene 4a (dlx4a)                                             4.77                          1.08E-07       3.21E-05                                                                      
  dpysl5a              dihydropyrimidinase-like 5a (dpysl5a)                                            7.65                          7.17E-08       2.49E 05                                                                      
  egfl6                EGF-like-domain, multiple 6 (egfl6)                                              10.45                         1.48E-09       4.05E-06                                                                      
  eno2                 enolase 2 (eno2)                                                                 7.00                          1.61E-07       4.05E-05                    7.17                                              1.43E-5
  ENSDART00000046209   Acbd7 protein                                                                    7.09                          3.48E-06       3.12E-04                                                                      
  **fabp7a**           **fatty acid binding protein 7, brain, a**                                       **19.77**                     **1.05E-09**   **3.90E-06**                **7.192**                                         **3.92E-8**
  fkbp10               Fkbp10 protein (Fragment)                                                        11.36                         2.20E-09       4.60E-06                    15.183                                            8.77E-6
  fkbp11               FK506 binding protein 11 (fkbp11)                                                15.02                         1.10E-08       8.95E-06                    2.424                                             5.93E-6
  fkbp11               FK506 binding protein 11 (fkbp11)                                                15.05                         3.29E-08       1.71E-05                    2.42                                              0.00000593
  fkbp7                FK506 binding protein 7 (fkbp7)                                                  8.90                          1.47E 07       3.82E 05                    3.214                                             5.47E-18
  fn1b                 fibronectin 1b (fn1b)                                                            5.43                          2.52E-06       2.58E-04                    5.654                                             6.59E-9
  fn1b                 fibronectin 1b (fn1b)                                                            9.14                          7.69E-07       1.20E-04                    5.65                                              6.59E-09
  **fstl1**            **follistatin-like 1 (fstl1)**                                                   **5.33**                      **9.83E-06**   **5.74E-04**                **3.823**                                         **7.45E-10**
  hrh3                 histamine receptor H3                                                            7.23                          8.70E-08       2.79E-05                                                                      
  hsp47                heat shock protein 47                                                            7.95                          2.34E-06       2.47E-04                                                                      
  hsp47                heat shock protein 47                                                            12.43                         9.08E-07       1.38E-04                                                                      
  **lamb1**            **laminin, beta 1 (lamb1)**                                                      **6.04**                      **3.88E-06**   **3.28E-04**                **4.786**                                         **1.92E-33**
  LOC555472            Novel protein similar to vertebrate cyclin M2 (CNNM2)                            6.54                          1.29E-06       1.70E-04                                                                      
  LOC557081            PREDICTED: similar to type VII collagen (LOC557081)                              5.39                          3.21E-07       6.73E-05                                                                      
  LOC557081            PREDICTED: similar to type VII collagen (LOC557081)                              5.54                          4.58E-07       8.52E-05                                                                      
  LOC557081            PREDICTED: similar to type VII collagen (LOC557081)                              6.00                          3.49E-07       7.10E-05                                                                      
  LOC560546            similar to Solute carrier family 2 member 10 (LOC560546)                         8.36                          4.39E-08       1.93E-05                                                                      
  LOC562671            PREDICTED: similar to Reticulocalbin (LOC562671)                                 5.93                          1.38E-08       9.76E-06                                                                      
  LOC562671            PREDICTED: similar to Reticulocalbin (LOC562671)                                 7.45                          5.28E-09       6.58E-06                                                                      
  LOC562849            PREDICTED: similar to Coronin, actin binding protein, 1C, transcript variant 1   6.91                          4.56E-08       1.95E-05                                                                      
  LOC562849            PREDICTED: similar to Coronin, actin binding protein, 1C, transcript variant 1   7.30                          4.81E-09       6.54E-06                                                                      
  LOC563353            similar to alpha 1 type XXI collagen precursor (LOC563353)                       7.83                          3.06E-08       1.63E-05                                                                      
  marcks               myristoylated alanine rich protein kinase C substrate (marcks)                   14.82                         6.85E-10       3.90E-06                    7.463                                             4.74E-16
  mdka                 midkine related growth factor (mdka)                                             10.30                         3.70E 09       6.22E 06                                                                      
  mdka                 midkine related growth factor (mdka)                                             14.77                         6.35E 09       6.84E 06                                                                      
  mmp13                matrix metalloproteinase 13 (mmp13)                                              12.73                         1.58E-09       4.05E-06                                                                      
  mmp13                matrix metalloproteinase 13 (mmp13)                                              16.80                         1.14E-09       3.90E-06                                                                      
  olfm2                olfactomedin 2 (olfm2)                                                           9.22                          2.12E-07       5.01E-05                                                                      
  **pcolce2b**         **procollagen C-endopeptidase enhancer 2b (pcolce2b)**                           8.23                          6.46E-08       2.41E-05                    **3.127**                                         **1.27E-9**
  **pdlim3**           **actinin-associated LIM protein (pdlim3)**                                      **11.13**                     **9.06E-09**   **8.07E-06**                **9.312**                                         **4.28E-7**
  **pea3**             **ETS-domain transcription factor pea3 (pea3)**                                  **4.06**                      **2.03E-06**   **2.27E-04**                **4.597**                                         **8.85E-11**
  pnoc                 prepronociceptin (pnoc)                                                          4.30                          1.26E-07       3.46E-05                                                                      
  prss35               protease, serine, 35 (prss35)                                                    8.36                          3.00E-08       1.63E-05                                                                      
  **rcn3**             **reticulocalbin 3, EF-hand calcium binding domain (rcn3)**                      17.56                         9.81E-09       8.56E-06                    **4.379**                                         **8.66E-5**
  rrbp1                ribosome binding protein 1 homolog (dog) (rrbp1)                                 17.53                         2.88E-10       3.14E-06                    10.201                                            3.06E-7
  sepn1                selenoprotein N, 1 (sepn1)                                                       8.98                          7.51E-08       2.56E-05                                                                      
  sepn1                selenoprotein N, 1 (sepn1)                                                       10.68                         4.30E-08       1.93E-05                                                                      
  shha                 sonic hedgehog a (shha)                                                          15.15                         1.55E-07       3.92E-05                                                                      
  **slc1a4**           **solute carrier family 1, member 4**                                            **12.08**                     **6.19E-09**   **6.84E-06**                **2.363**                                         **7.32E-6**
  sp5                  Sp5 transcription factor (sp5)                                                   5.41                          4.04E-07       7.94E-05                                                                      
  TC301719             Tenascin-C, complete                                                             43.75                         8.51E-09       7.91E-06                    5.608                                             1.35E-7
  TC328915             Spalt 1, partial (9%)                                                            5.50                          8.55E-07       1.30E-04                                                                      
  TC350566             Actinin-associated LIM protein, partial (45%)                                    8.02                          1.19E-08       9.32E-06                                                                      
  TC363066             Keratin 18 (Dorsal aorta proneprin kinesin-1), partial (45%)                     10.37                         4.19E-09       6.31E-06                                                                      
  tnc                  tenascin C (tnc)                                                                 21.46                         2.48E-09       4.71E-06                    5.61                                              1.35E-7
  tubb5                tubulin, beta 5 (tubb5)                                                          41.42                         1.93E-09       4.60E-06                                                                      
  tubb5                tubulin, beta 5 (tubb5)                                                          41.54                         2.53E-09       4.71E-06                                                                      
  zic3                 zic family member 3 heterotaxy 1 (odd-paired homolog, Drosophila) (zic3)         4.33                          9.55E-06       5.65E-04                                                                      

Genes are in alphabetical order.

![](oncotarget-07-71567-i001.jpg) over expressed in melanoma vs normal.

**Bold** over expressed in melanoma vs other cancers.

![](oncotarget-07-71567-i002.jpg) Gene is associated with poor survival see (figure [6](#F6){ref-type="fig"}).

![(**A**) Gene products for melanoma overexpressed genes were screened for staining in patient melanoma using the Protein Atlas database. The circle for each protein shows the overview of the stained tumor tissue, the square directly below a magnification of a representative region of the tumor (zoom, bar = 100 μm), and the square below a magnified section of normal skin (bars = 100 μm). 1: myristoylated alanine-rich protein kinase C substrate, 2: FK506 binding protein 7, 3: FK506 binding protein 10, 65 kDa, 4: FK506 binding protein 11, 19 kDa, 5: ribosome binding protein 1, 6: solute carrier family 1 (glutamate/neutral amino acid transporter), member 4. (**B**) Summary of staining intensities for indicated proteins were inferred from Protein Atlas data.](oncotarget-07-71567-g002){#F2}

Protein expression in melanoma and normal skin {#s2_2}
----------------------------------------------

Protein location, staining intensity and quantity of tumor cells stained (in percent) was inferred from the Protein Atlas database. Protein localization was found to be cytoplasmic or membranous for all, except for BCAN where in addition nuclear staining was observed and for PEA3/ETV4 were exclusive nuclear staining was found (Figure [2A](#F2){ref-type="fig"}). Staining intensities for proteins were summarized in Figure [2B](#F2){ref-type="fig"}.

Oncomine heatmaps: *BAMBI* and *FKBP10* {#s2_3}
---------------------------------------

*BAMBI* expression (5.556-fold up in melanoma vs normal skin and 10.7-fold vs other cancers) has not been previously associated with melanoma. We compared *BAMBI* expression in a panel of 19 different tumor cell types, and found overexpression most prominent in melanoma cell lines (*n* = 41; Figure [3A](#F3){ref-type="fig"}). Moreover, when associating a given gene expression pattern with a predefined expression signature of a biological theme such as angiogenesis, five genes with known implication in this process were also upregulated more than 1.5-fold (*P* \< 0.001) and co-expressed with *BAMBI*. These genes were *NRP2*, *ANGPTL1*, *RHOB*, *IL8* and *KDR* (Figure [3A](#F3){ref-type="fig"}). *BAMBI* is also expressed in capillaries in developing mouse embryos, as revealed by *in situ* hybridization (Figure [3B](#F3){ref-type="fig"}). These data suggest an implication of *BAMBI* expression in melanoma angiogenesis. When compared to other types of skin cancer such as basal cell carcinoma or squamous cell carcinoma, *BAMBI* showed selective overexpression in melanoma and strong co-expression (0.815) with the established melanoma gene *EDNRB*, but also with *HEY1* (0.759), a gene important for vascular development (Figure [4](#F4){ref-type="fig"}).

![Five genes of the Oncomine angiogenesis gene signature were co-regulated with Bambi transcripts in melanoma compared to other cancers (\> 1.5-fold-change, *p* \< 0.001)\
*NRP2*, *ANGPT1*, *RHOB*, IL8 and *KDR*. (**B**) *In situ* hybridization of *BAMBI* mRNA in 14.5 days old mouse embryos shows expression in capillaries of the brain (arrows, magnifications of the square in the lower images).](oncotarget-07-71567-g003){#F3}

![*BAMBI* expression in melanoma strongly correlates with *EDNRB*, encoding for endothelin receptor type B (arrows), an established gene implicated in melanocyte induction and melanoma progression\
Note also strong correlation with *HEY1* (asterisk), a gene important for embryonic angiogenesis.](oncotarget-07-71567-g004){#F4}

Other regeneration genes overexpressed in melanoma encode for FKBP proteins (FK506-binding proteins). *FKBP7*, *FKBP11* and *FKBP10*, upregulated 3.21, 2.42 and 15.18-fold, respectively, have not yet been described in skin cancer. We focused on *FKBP10* because of its strong expression in melanoma (up 15.18-fold, Table [1](#T1){ref-type="table"}). In a co-expression analysis across epithelial cell lines transfected with different oncogenes, *FKBP10* was exclusively associated with *HRAS* transfection (Figure [5](#F5){ref-type="fig"}). Mice with aberrant *HRAS* activity develop melanoma \[[@R10]\]. Interestingly, when an additional selection criterion was added (Oncomine regeneration gene signature), expression of a number of important genes belonging to chemokine families (*CXCL5*, *CXCL2*, *CXCL3*), proteases (*MMP10*, *MMP1*, *MMP14*) as well as angiogenic genes (*VEGF*, *ANGPTL4*) was very strongly correlated with *FKBP10* expression (0.822). These data suggest that expression of FKBP10 protein might play a role in tissue regeneration, angiogenesis and, as other regeneration genes, in melanoma progression.

![Cluster analysis of the Oncomine regeneration gene signature co-expressed with *FKBP10* gene in transfected human epithelial cells\
Transfected genes are indicated at the bottom. *FKBP10* is selectively induced in *HRAS*-transfected cells and important known regeneration and angiogenic genes such as *MMP*s, *VEGF* and *CXCL* chemokines are significantly co-expressed with *FKBP10*.](oncotarget-07-71567-g005){#F5}

High expression of *FKBP7, DPYSL5 and MDK* is associated with poor patient survival {#s2_4}
-----------------------------------------------------------------------------------

We performed TCGA patient survival analysis integrating all 54 regeneration genes expression. We compared the survival of patients with the highest expression for each gene (75th percentile) with the remaining patients (normal expression). For three genes *DPYSL5*, *FKBP7* and *MDK* we observed significant differences in survival between the two groups (Figure [6](#F6){ref-type="fig"}). We observed a similar difference in survival for *MCM4* gene, previously reported as a prognostic marker in melanoma \[[@R11]\]. These data suggest that high expression of *DPYSL5*, *FKBP7* and *MDK* can be novel potential prognostic marker for melanoma.

![Survival curves of patients with skin cutaneous melanoma\
For each gene, the red curve represents mortality in patients with a high expression of given gene (expression values above the 75^th^ percentile). The black line represents survival in the remaining patients with lower gene expression levels (0--75^th^ percentile). *P*-values and the median survival for each group are indicated as well as difference in survival (number of days). Note that the *P*-value for the described MM survival gene MCM4 is very close to significance in the TCGA dataset used for this study.](oncotarget-07-71567-g006){#F6}

DISCUSSION {#s3}
==========

In this paper, we used an *in silico* approach to identify novel genes implicated in cancer. Other computational approaches have recently been developed to model associations of gene networks, metabolic pathways and response to treatment \[[@R12]\]. To evaluate the biological significance of our regeneration data, we compared expression of the most regulated genes to a pathological context. We focused on melanoma, because of strong relationships between melanocyte differentiation during blastema formation and deregulation of melanocyte differentiation program during melanoma progression \[[@R2]\]. Importantly, two genes encoding for known melanoma-promoting proteins were present in our list, such as the extracellular matrix proteins tenascin C (up 5.608-fold) \[[@R4]\] and fibronectin (up 5.654-fold) \[[@R13]\], suggesting that yet unexplored genes participating in blastema regeneration may also have a role in melanoma formation.

The role of BAMBI in melanoma progression has yet to be established. Its expression is inversely correlated with the metastatic potential of melanoma \[[@R14]\]. Oncomine data show that it is expressed by most melanoma cell lines (Figures [3A](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}), but also by capillaries and endothelial cells \[[@R15]\] where it negatively regulates angiogenesis \[[@R16]\]. It might therefore be that BAMBI controls excessive tumor angiogenesis thereby allowing a more efficacious vascularization, similarly to previously described pro- and anti-angiogenic regulators in tumors \[[@R17]\]. Interestingly, Bambi is co-expressed with a well-known melanoma-associated gene, *EDNRB*, important for angiogenesis \[[@R2]\] (Figure [4](#F4){ref-type="fig"}) suggesting that *BAMBI* is a part of a network of genes regulating vascular growth in melanoma. This idea is further supported by co-expression *BAMBI* with *HEY1*, a downstream effector of Notch signaling important for developmental angiogenesis \[[@R18]\] (Figure [4](#F4){ref-type="fig"}). Interestingly, Bambi expression in melanoma is regulated by connective tissue growth factor (*CTGF*) since siRNA-mediated knock-down of *CTGF* reduces Bambi expression in melanoma cell lines \[[@R19]\]. Evidence for *BAMBI* implication in melanoma comes mainly from transcript overexpression since protein levels are low (Figure [2B](#F2){ref-type="fig"}). This may be explained by a rapid degradation of BAMBI protein by lysosomal and autolysosomal mechanisms \[[@R15]\]. *BAMBI* has been found to be part of a gene signature overexpressed in multiple myeloma and pluripotent stem cells \[[@R20]\]. Melanoma stem cells are thought to drive metastasis and tumor progression \[[@R21]\]. It is tempting to speculate that BAMBI participates in melanoma progression via influencing stem cell differentiation or participating in leukocyte mimicry of circulating melanoma cells.

FK506-binding proteins are increasingly discussed as a novel anti-cancer targets \[[@R8]\]. FKBP10 play an important role in human tissue homeostasis because mutations in this gene cause a severe form of osteogenesis imperfecta \[[@R22]\]. Our data suggest that FKBP10 could be a potential target in melanoma treatment, since HRAS specifically induces *FKBP10* expression (Figure [5](#F5){ref-type="fig"}). *HRAS* overexpression causes melanoma in mice \[[@R10]\] and melanocyte-specific expression of oncogenic *HRAS* has been shown to induce melanoma in zebrafish \[[@R23]\]. HRAS also has an established role in angiogenesis \[[@R24]\].

Other genes whose protein products have evidence of function in cancer include RCN3, RRBP1, PDLIM3 and SLC1A4. Nothing is known about reticulocalbin (RCN3), the protein with highest melanoma expression in the Protein Atlas, but recently, RCN1, a paralog of RCN3, has been found to be a promising tumor marker for renal cell carcinoma \[[@R25]\]. RRBP1 is overexpressed in lung cancer and promotes tumor cell survival \[[@R26]\]. Functions of PDLMI3 in melanoma development can only be speculated; in the adult, the protein is expressed in muscle and plays a role in disorders such as myotonic dystrophy type 1 (DM1) \[[@R27]\] and SLC1A4 has been shown to be induced by the transcription factor MITF in the melanoma cell line SK-MEL-28 \[[@R28]\]. Nuclear expression of PEA3/ETV4 in melanoma may be directly linked to activation of a pro-metastatic program through activation of FAK (Focal adhesion kinase) genes \[[@R29]\].

We identified three genes overexpressed in regenerating blastema that are predictors of poor survival in melanoma patients. As a positive control, we included MCM4, which has been shown to be a poor melanoma survival gene in an independent study \[[@R11]\]. Midkine, a heparin-binding multifunctional growth-promoting protein is overexpressed in various solid tumours and high expression has been shown to be associated with poor survival in breast and lung cancer \[[@R30], [@R31]\]. The role of midkine in melanoma pathogenesis has not yet been investigated. It is expressed in keratinocytes, not melanoma cells, but recombinant midkine stimulates cell proliferation \[[@R32]\]. It might therefore act as a paracrine growth factor for malignant melanoma cells.

Interestingly, *DPSYL5* (also known as *CRMP5*), a gene which controls brain development, has been shown to promote glioblastoma cell growth and is a potent prognostic factor for this disease, with high expression predicting dismal prognosis \[[@R33]\]. Since melanocytes and glial cells are derived from neural crest precursor cells and share responsiveness to differentiation factors \[[@R34]\], it is possible that the poor prognosis associated with *DPSYL5* in melanoma is due to the common developmental origin with glial cells.

*FKBP7* is upregulated in melanoma compared to other cancers (Table [1](#T1){ref-type="table"}). In the paper by Crijns et al., *FKBP7* is described as one of 86 genes associated with low survival in ovarian cancer patients \[[@R35]\]. This is of interest, since proteins of the FKBP family can be targeted by chemical compounds such as rapamycin and its derivatives and constitute therefore promising potential targets for anti-cancer treatment.

Taken together, our data show that genes expressed in a highly controllable system, the zebrafish fin regeneration, recapitulate expression patterns observed in severe human pathologies such as melanoma. Several of the genes and proteins presented here are overexpressed in melanoma and warrant further validation as potential novel melanoma markers or therapeutic targets.

MATERIALS AND METHODS {#s4}
=====================

Zebrafish fin amputation and regeneration {#s4_1}
-----------------------------------------

Wild-type zebrafish (*Danio rerio*) were purchased from the ZIRC fish center (University of Oregon, USA), and kept in an aquatic holding facility in INSERM zebrafish facilities under standard conditions. Fish housing and handling was performed as described \[[@R36]\]. In brief, fish were stored in tanks for at least 3 weeks before experimentation. The photoperiod was 10-h dark/14-h light cycle and water temperature was maintained at 28 ± 1°C throughout holding and during experiments. Ethical approval for all animal studies was obtained from the institutional animal care and use committee of the INSERM in accordance with the national advisory committee for laboratory animal research guidelines licensed by French authority. For zebrafish fin regeneration assay, adult fish of at least 10 weeks were anesthetized by addition of 0.6 mM tricaine (ethyl-m-aminobenzoate) to water. Caudal fins were amputated at a level proximal to first bifurcation of the bony rays using a scalpel (Figure [1A](#F1){ref-type="fig"}). After three days, blastema and control fin tissues were harvested and processed for microarrays \[[@R37]\].

Blastema microarray analysis and statistics {#s4_2}
-------------------------------------------

Gene expression of regenerating blastema vs. control fins was analysed by Agilent Zebrafish Oligo Microarray V2 4 × 44K (ref. G2519F) using standard protocols \[[@R37]\]. Overall gene selection procedure is illustrated in Figure [1B](#F1){ref-type="fig"}. Total RNA was extracted from stump control and regenerated fins using the NucleoSpin^®^ RNA II kit (Macherey-Nagel, Germany), according to the manufacturer\'s instructions. Purity of RNA samples was evaluated and RNA integrity was controlled on a Bioanalyzer 2100 (Agilent Technologies, USA). Target preparation and hybridization were done according to the manufacturer\'s instructions. Internal standards were derived from the Two-Color RNA Spike-in Kit (Agilent Technologies, USA). The labeled targets were purified using the RNeasy^®^ Mini Kit (Qiagen) and 825 ng of Cy3- and Cy5-labeled cRNA targets were mixed and incubated on the microarray slides in a rotating oven, at 65°C for 17 hours. Biological samples from three blastema and four normal fin controls (Cy3) were hybridized against a common reference control (Cy5). After washing, slides were scanned using a microarray scanner (Agilent Technologies, USA) at 5-μm resolution and at high and low photomultiplier voltages to optimize the dynamic range of image quantification. The data were extracted from these images using the Agilent Feature Extraction v.9.5.3 software. Data were analyzed with *limma* R/Bioconductor package \[[@R38]\]. Arrays were background corrected using minimum method and a "within-array" loess normalization was performed \[[@R39]\]. Finally, array data were normalized using quantile normalization. We applied the linear modeling approach implemented by *lmFit* and the empirical Bayes statistics implemented by *eBayes* to find genes deregulated in blastema as compared to normal fin. Results were considered statistically significant at *q*-values ≤ 0.05 and fold-change ≥ 4. Microarray data sets have been deposited at NCBI\'s Gene Expression Omnibus (GEO series accession number GSE58567).

Protein expression in melanoma and normal skin {#s4_3}
----------------------------------------------

The Protein Atlas database ([www.proteinatlas.org](http://www.proteinatlas.org/)) \[[@R40]\] was used to retrieve immunhistochemical expression data of melanoma and normal skin.

Below is a table of the patients/antibodies used together with accompanying histological data.

For skin control histology, sections stained by the following antibodies (Protein Atlas abbreviations) were selected: Brevican: HPA007865; Calumenin: HPA006018; Tenascin C: HPA004823; Marcks: CAB022062; FKBP7: HPA008707; FKBP10: HPA051171; FKBP11: HPA041709; S100B: HPA015768; SLC1A4: CAB002757; Reticulocalbin 3: HPA043134; PDZ And LIM Domain Protein 3: HPA004749; RRBP1: HPA009026. Bambi: HPA10866. No useful normal skin data were found for PEA3/ETV4.

Oncomine gene expression analysis {#s4_4}
---------------------------------

To focus on genes, which were consistently upregulated in regenerating blastema, we applied a cut-off value of 4. We then used Oncomine™ version 3 and 4.2 (Compendia Bioscience, Ann Arbor, MI, USA \[[@R3]\]) for analysis and visualization of expression data. These data were obtained from the Riker_Melanoma study (*n* = 4 controls; 14 melanoma patients) or the Talantov_Melanoma study (*n* = 7 controls; 45 melanoma patients). The following parameters were included in the search (primary filters): Gene name; Analysis Type: Cancer vs. Normal Analysis and Cancer Type: Melanoma. Expression data of regeneration genes in melanoma compared to othercancers were obtained from the Barrettina_CellLine study (57 melanoma samples vs. 17 other types of cancer), Wagner_CellLine study (18 melanoma samples vs. 3 other cancers), Scherf_CellLine (10 melanoma samples vs. 10 other cancers) and Shankavaram_CellLine 2 study (10 melanoma samples vs. 10 other cancers). The Riker_melanoma study was also used to find genes co-expressed with *BAMBI*.

For concept gene signature studies, we used the following search criteria: Gene: *BAMBI*; Concept: angiogenesis -- GO Biological process; Cancer type: melanoma; Concept type: Overexpression. The Garnett_Cellline study was retained for Cluster analysis. For the second concept study we used: Gene name: *FKBP10*; Concept: tissue regeneration -- GO Biological process; Analysis type: Co-expression analysis. The Bild_Celline study was retained and group by perturbation was selected (Human Mammary Epithelial Cells Primary Culture). Details on the statistical methods underlying Oncomine have been detailed elsewhere \[[@R41]\].

*In silico in situ* hybridization {#s4_5}
---------------------------------

For *in situ* hybridization of Bambi expression, we used the GenePaint database \[[@R42]\], which provides access to high quality *in situ* hybridization images of sections of E14.5 mouse embryos. Capillary expression of BAMBI was demonstrated in the brain.

Survival analysis of TCGA patients integrating gene expression {#s4_6}
--------------------------------------------------------------

Clinical data and RNAseq gene expression for 472 skin cutaneous melanoma samples from the Cancer Genome Atlas (TCGA) were downloaded using FireBrowse (<http://gdac.broadinstitute.org/>) and normalized with *voom* from the *limma* package. Survival of patients with gene expression above the 75th percentile (classified as high expression) was compared to the remaining patients (normal expression) using the package *survival* in R ([http://www.R-project.org/](http://www.r-project.org/)).

  Protein         Antibody ID\*   Patient     Diagnosis                                             Patient id
  --------------- --------------- ----------- ----------------------------------------------------- ------------
  **FKBP7**       HPA008707       M, age 41   MM\*\*, Metastatic site (M-87206)                     2112
  **FKBP10**      HPA051171       F, age 91   MM, NOS (M-87203)                                     3887
  **FKBP11**      HPA041709       F, age 52   MM, NOS (M-87203)                                     4018
  **TNC**         HPA004823       M, age 53   MM, NOS (M-87203)                                     2534
  **MARCKS**      CAB022062       F, age 81   MM, NOS (M-87203)                                     3210
  **BAMBI**       HPA10866        M, age 41   MM, Metastatic site (M-87206)                         2112
  **BCAN**        HPA007865       F, age 30   MM, Metastatic site (M-87206), Pancreas (T-59000)     2598
  **PDLIM3**      HPA004749       M, age 59   MM, Metastatic site (M-87206), Lymph node (T-08000)   1414
  **RCN3**        HPA043134       M, age 84   MM, NOS (M-87203)                                     4028
  **SLC1A4**      HPA034964       F, age 64   MM, NOS (M-87203)                                     4026
  **CALUA**       HPA006018       F, age 56   MM, Metastatic site (M-87206), Skin (T-01000)         1220
  **RRBP1**       HPA009026       F, age 81   MM, NOS (M-87203)                                     3210
  **PEA3/ETV4**   HPA005768       F, age 46   MM, NOS (M-87203)                                     3223
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